Start an analysis for ESLA
Estrella Immunopharma, Inc.
Stock · NASDAQProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $1m | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Remaining authorization | $1mEST | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Program expiry | n/a | — | |
| Repurchased last quarter | Not found in filings | — | |
| Has used an ASR | No | — |
Remaining authorization is estimated: we derive it from reported spend, or convert a share authorization at the latest close. Check the linked filings.
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| 30-Jan-24 | $1m | $1mEST | n/a | On January 30, 2024, the Company issued a press release announcing that its Board of Directors has authorized share repurchases of up to $ 1.0 million of its common stock.10-Q filed 13-Nov-26 |
Open-market repurchases
None reported in the filings we hold.